![]() | ![]() |
Formats:
|
||||||||||||||||||||||||
Copyright © 2007, The Rockefeller University Press Article Eps15 and Dap160 control synaptic vesicle membrane retrieval and synapse development 1Graduate Program in Developmental Biology, 2Department of Molecular and Human Genetics, 3Department of Neuroscience, and 4Howard Hughes Medical Institute, Baylor College of Medicine, Houston, TX 77030 5Department of Genetics, University of Cambridge, Cambridge CB2 3EH, England, UK 6Department of Neuroscience, Karolinska Institutet, SE-171 77 Stockholm, Sweden 7Institute of Biomedical and Clinical Sciences, Peninsula College of Medicine and Dentistry, Plymouth PL6 8BU, England, UK Correspondence to Cahir J. O'Kane: c.okane/at/gen.cam.ac.uk; or Hugo J. Bellen: hbellen/at/bcm.tmc.edu Received January 5, 2007; Accepted June 18, 2007. This article has been cited by other articles in PMC.Abstract Epidermal growth factor receptor pathway substrate clone 15 (Eps15) is a protein implicated in endocytosis, endosomal protein sorting, and cytoskeletal organization. Its role is, however, still unclear, because of reasons including limitations of dominant-negative experiments and apparent redundancy with other endocytic proteins. We generated Drosophila eps15-null mutants and show that Eps15 is required for proper synaptic bouton development and normal levels of synaptic vesicle (SV) endocytosis. Consistent with a role in SV endocytosis, Eps15 moves from the center of synaptic boutons to the periphery in response to synaptic activity. The endocytic protein, Dap160/intersectin, is a major binding partner of Eps15, and eps15 mutants phenotypically resemble dap160 mutants. Analyses of eps15 dap160 double mutants suggest that Eps15 functions in concert with Dap160 during SV endocytosis. Based on these data, we hypothesize that Eps15 and Dap160 promote the efficiency of endocytosis from the plasma membrane by maintaining high concentrations of multiple endocytic proteins, including dynamin, at synapses. Introduction Endocytosis is crucial for the reformation of functional synaptic vesicles (SVs) after exocytosis of neurotransmitters. Although multiple mechanisms have been observed during SV endocytosis (Gad et al., 2000; Teng and Wilkinson, 2000; Sun et al., 2002; Granseth et al., 2006; He et al., 2006), all of these involve the detachment of the vesicle from the plasma membrane, a step that is known as fission. Current evidence indicates that the GTPase dynamin functions at the fission step. For example, endocytic vesicles are arrested at the fission step in shibirets1, a temperature-sensitive mutant of dynamin, and in the presence of the nonhydrolyzable analogue of GTP (Kosaka and Ikeda, 1983; Takei et al., 1998). As inhibition of dynamin leads to complete blockage of SV endocytosis in shibire mutants, dynamin activity is absolutely required for SV endocytosis (Koenig and Ikeda, 1989; Shupliakov et al., 1997; Verstreken et al., 2002; Poskanzer et al., 2003). To further understand dynamin function, we and others have previously characterized a major binding partner of dynamin, Dap160 (dynamin-associated protein 160 kD) and shown that it maintains proper dynamin localization at synapses (Broadie, 2004; Koh et al., 2004; Marie et al., 2004; Evergren et al., 2007). Although there is a complete block in endocytosis during inhibition of dynamin function, residual endocytic activity persists in the absence of Dap160. This prompted us to study other proteins that may function in conjunction with dynamin. EGF receptor pathway kinase substrate clone 15 (Eps15) has been found in protein complexes with multiple endocytic proteins, including dynamin and the vertebrate homologue of Dap160, intersectin (Santolini et al., 1999; Sengar et al., 1999; Salcini et al., 2001). Originally discovered as an EGF receptor kinase substrate and a putative oncogene, Eps15 was later implicated in endocytosis and endosomal trafficking by in vitro studies (Fazioli et al., 1993; Tang and Cai, 1996; Tebar et al., 1996; Wendland et al., 1996; Carbone et al., 1997; Benmerah et al., 1999; Torrisi et al., 1999; Bache et al., 2003). Intriguingly, RNA interference knockdown of Eps15 in a nonneuronal cell line indicated that Eps15 is redundant with other endocytic proteins during the endocytosis of EGF receptor (Sigismund et al., 2005). This prompted several groups of investigators to examine its role in SV endocytosis. In Caenorhabditis elegans, eps15-null mutants undergo a temperature-sensitive paralysis, and mutant nerve terminals exhibit vesicle depletion at high temperatures, indicating a role for Eps15 in maintaining the presence of SVs at the nerve terminals (Salcini et al., 2001). More recently, a Drosophila mutant with reduced Eps15 levels was shown to undergo impairment in neurotransmission and paralysis only at high temperatures but not at physiological temperatures (Majumdar et al., 2006). In contrast, injection of dominant-negative peptides to inhibit Eps15 function in squid axonal terminals leads to a very subtle decrease in the number of SVs but a strong inhibition of neurotransmitter release (Morgan et al., 2003). The in vivo data therefore suggest that Eps15 plays either an accessory role or no role in endocytosis. We therefore decided to generate eps15 protein-null alleles and investigate the role of Eps15 in flies in more detail. Here, we describe the functional characterization of Drosophila Eps15 to address the following questions: (1) Does Eps15 function in endocytosis of SVs from the plasma membrane at the nerve terminal? (2) If so, at which step is Eps15 involved? (3) Is there a functional relationship between Eps15 and Dap160? Our data indicate that Eps15 is required for efficient SV endocytosis and that loss of Eps15 causes a very severe reduction in dynamin and Dap160 protein levels at neuromuscular junctions (NMJs). Furthermore, the endocytic defects of eps15- and dap160-null mutations are not additive, suggesting that Eps15 and Dap160 act at the same step during endocytosis. Results Drosophila eps15 is an essential gene The Drosophila genome contains a single homologue of mammalian Eps15 (Lloyd et al., 2000). It has three Eps15 homology (EH) domains, a coiled coil domain, a region with multiple DPF (aspartate-proline-phenylalanine) motifs, and at least one, possibly two, ubiquitin-interacting motifs (UIMs) at the C terminus, similar to its mammalian homologue (Fig. S1 A, available at http://www.jcb.org/cgi/content/full/jcb.200701030/DC1; Polo et al., 2002). To determine its spatial and subcellular distribution, we raised two different polyclonal antibodies against epitopes shown in Fig. S1 A: a rabbit antibody and a guinea pig antibody. Both antibodies are specific, as mutants that lack the eps15 gene display no immunoreactivity on Western blots (Fig. 1 D
To determine the function of Eps15 in vivo, we disrupted the eps15 gene using two different reverse genetic approaches. We imprecisely excised EP2513, a semilethal P element insertion in the 5′ untranslated region of the eps15 gene (Fig. 1 B To determine which mutations correspond to null alleles, we performed Western blot analyses. The eps15e75/eps15e75 and eps15e75/eps15Δ29 animals do not express detectable levels of Eps15 protein on Western blots (Fig. 1 D Eps15 is enriched at synapses in the SV pool and migrates to the plasma membrane during stimulation To determine where Eps15 is expressed, we performed immunohistochemistry of third instar larvae (Bellen and Budnik, 2000). Both anti-Eps15 antibodies reveal the same expression profiles, and this immunoreactivity is lost in null mutant animals, indicating that the labeling is specific (Fig. 2 A At the NMJ, Eps15 is present in the central region of the boutons in a honeycomb-like pattern, where most Eps15 staining was found surrounding active zones, defined by anti-Bruchpilot/nc82 (Fig. 2 D
Eps15 regulates neuromuscular synapse development A larval NMJ typically consists of a series of boutons connected by neurites, like beads on string. These boutons are dynamic structures that sprout and retract during larval development (Eaton et al., 2002). Because Dap160 mutants display numerous extra NMJ boutons and branching (Koh et al., 2004; Marie et al., 2004), and because Eps15 and Dap160 interact, we quantified the number of boutons and branches in eps15 mutant NMJs. Compared with controls, mutant larvae show a pronounced increase in bouton number at three different NMJ synapses (Fig. 4, A–D and F
Eps15 is required to sustain high-frequency neurotransmitter release Eps15 has been implicated in endocytosis and endosomal trafficking (Tebar et al., 1996; Benmerah et al., 1999; Torrisi et al., 1999; Bache et al., 2003). In addition, loss of Eps15 in C. elegans leads to a defect in vesicle cycling at the restrictive temperature (Salcini et al., 2001). To define the role of Eps15 in the SV cycle more precisely, we performed electrophysiological assays of mutant eps15 NMJs. To determine whether the exocytic machinery is intact, we elicited low-frequency stimuli and recorded evoked excitatory junctional potentials (EJPs) in 0.5, 1, and 5 mM extracellular Ca2+. Under these conditions, the EJPs are similar to wild-type amplitudes (Fig. 5 A
To determine whether eps15 mutant NMJs are able to efficiently recycle vesicles under repetitive stimulation, we applied 10 Hz of stimulation for 10 min in 5 mM extracellular Ca2+. Control NMJs are able to maintain EJPs at ~90% of the initial amplitudes, but eps15 NMJs show a strong synaptic depression to <40% of initial EJP amplitudes (Fig. 5 D Eps15 is required for efficient SV endocytosis One possible cause for the vesicle recycling defect in eps15 mutants is impaired endocytosis. To assay for endocytosis at the NMJs, we performed dye uptake experiments by applying a strong stimulus of 90 mM K+ and 5 mM Ca2+ in the presence of the styryl dye FM1-43FX. Compared with controls, ~50% of dye uptake remains in the partial loss-of-function mutant eps15EP2513/eps15EP2513, whereas only ~20% of dye uptake remains in the eps15-null mutants, eps15e75/eps15Δ29 and eps15Δ29/eps15Δ29 (Fig. 6
Endocytosis from the plasma membrane consists of sequential steps that can be observed with transmission EM (TEM). To further investigate the endocytic defect in eps15 mutants, we quantified vesicle density and size of boutons in the resting state, during a strong stimulation with 90 mM K+, and recovery after stimulation (Fig. 7, A–F
Because intense stimulations reveal reduced FM1-43FX uptake and more severe synaptic depression at eps15 NMJs compared with controls, we applied 90 mM K+ stimulation to control and eps15 mutant boutons before processing for TEM. As shown in Fig. 7 (C, D, and G) The presence of large cisternae in eps15 mutant boutons is reminiscent of dap160 mutant boutons after a 1-min recovery from stimulation (Koh et al., 2004). This prompted us to examine dap160 mutant bouton morphology during stimulation in more detail. As seen in eps15 mutants, we observe cisternae and large membraneous bodies that appear to be contiguous to the plasma membrane (Fig. 7, M and N Eps15 maintains proper levels of dynamin and Dap160 at NMJs The endocytic defects, in particular, the retrieval defects observed by TEM in eps15 mutants resemble those observed in dap160 mutants (Koh et al., 2004; Marie et al., 2004; Fig. 7, K–N
The severe reductions of dynamin and Dap160 at eps15 mutant NMJs suggest that these two proteins are critical partners of Eps15 in endocytosis. We then asked whether the reductions of these two proteins are restricted to the synapse. Western blots of third instar larval brains indicate a subtle reduction of Dap160 levels and normal dynamin levels in the central nervous system (Fig. S3, available at http://www.jcb.org/cgi/content/full/jcb.200701030/DC1), suggesting that the reductions of these two proteins in eps15 mutants occur predominantly at the synapse. The C-terminal domains of Eps15 are not essential for SV endocytosis and synapse development Because Eps15 possesses different domains that biochemically interact with various protein partners, it is possible that different domains are involved in distinct processes. To address this possibility, we verified the binding properties of three major protein–protein interaction domains of Eps15 using in vitro binding assays. Consistent with similar studies on the mammalian Eps15, the EH-, DPF- and the UIM-containing regions of Drosophila Eps15 bind Dap160, α-adaptin, and ubiquitin, respectively (Fig. S4, available at http://www.jcb.org/cgi/content/full/jcb.200701030/DC1; Benmerah et al., 1998; Sengar et al., 1999; Polo et al., 2002). We then tested the requirement of N- and C-terminal domains of Eps15 in SV endocytosis and synaptic bouton development by neuronally expressing three eps15 cDNA constructs in the eps15-null background: (1) a full-length eps15 cDNA (Eps15wt), (2) a truncated cDNA encoding only the N-terminal EH domains and coiled coil domains (ΔDPF; Fig. S1 A), and (3) a full-length cDNA with point mutations in the EH domains (EHmut; unpublished data). It is expected that the ΔDPF truncation protein will lose the ability to interact with α-adaptin and ubiquitinated proteins, whereas the EHmut protein will only lose the ability to bind Dap160 and other EH binding proteins (Benmerah et al., 1999; Santolini et al., 1999). EHmut is expressed but fails to localize at the NMJ and was not further analyzed (unpublished data). Eps15wt and ΔDPF are expressed and localized normally at the NMJ and rescue eps15e75/eps15Δ29 to normal adults (unpublished data). This allowed us to assess the function of ΔDPF at the NMJ with respect to synaptic bouton development and SV endocytosis. To determine the contributions of Eps15 domains to synaptic bouton development, we quantified bouton numbers of the muscle 6/7 synapses (Fig. 9 B Given the importance of α-adaptin in endocytosis, we asked whether a truncated Eps15 protein without the α-adaptin binding motifs can function normally in SV endocytosis by performing an FM1-43FX uptake assay. We observed rescue of the FM1-43FX uptake in eps15-null mutants by neuronal expression of Eps15wt and ΔDPF (Fig. 9 C Eps15 and Dap160 function at the same endocytic step Several observations suggest a functional relationship between Eps15 and Dap160. First, Eps15 and Dap160 physically bind to each other and colocalize at NMJs (Fig. 1 A To investigate the functional relationship between Eps15 and Dap160, we determined the endocytic defects of eps15 and dap160 mutants in double mutant larvae. First, we examined the lethal phases of double mutants and show that dap160- and eps15-null mutants live to pharate adult stage, similar to the single eps15- and dap160-null mutants. Second, dap160- and eps15-null mutants show normal evoked EJPs in response to single stimuli and during 10 Hz of stimulation; hence, these double mutants also show the same depression kinetics as the eps15- and dap160-null single mutants (Fig. 10, A and B
Discussion Eps15 stabilizes multiple proteins in the presynaptic compartment eps15 mutant NMJs exhibit a severe reduction in dynamin and Dap160 protein levels, suggesting a functional relationship between these proteins and Eps15. At the same time, we observe relatively mild reductions of α-adaptin, Stoned B, synaptotagmin I, and endophilin. The reduction of protein levels of dynamin, Dap160/intersectin, α-adaptin, and Stoned B in eps15 mutants may be accountable by the interaction of these proteins with Eps15 (Benmerah et al., 1999; Sengar et al., 1999; Martina et al., 2001; Salcini et al., 2001; Fig. 1 A Eps15 and Dap160 are required to maintain proper levels of dynamin at the NMJ The endocytic defect in eps15 can be largely ascribed to impaired vesicle budding from plasma membrane and cisternae. Compared with control boutons, stimulations of eps15 mutant boutons result in more severe vesicle depletions, concurrent with the appearance of cisternae and large invaginations, which appear to be contiguous with the plasma membrane (Fig. 7, K and L The endocytic intermediates found in eps15 mutants resemble those observed when dynamin or Dap160 function is perturbed. Cisternae and invaginations contiguous with the plasma membrane have been reported at neuronal synapses during genetic or dominant-negative peptide perturbations of dynamin function in Drosophila and lampreys, respectively (Kosaka and Ikeda, 1983; Koenig and Ikeda, 1989, 1996, 1999; Koenig et al., 1993; Shupliakov et al., 1997). We have previously reported that dap160 mutant NMJs show accumulation of cisternae during recovery from stimulation (Koh et al., 2004). Here, we fixed dap160 mutants during stimulation and observed severe vesicle depletion concurrent with large invaginations from the plasma membrane, similar to those observed in eps15. Because dynamin levels are severely reduced at eps15 and dap160 NMJs, it is likely that both Eps15 and Dap160 act in concert to maintain high concentrations of dynamin at the synapse. Indeed, dap160 eps15 double mutants show the same defects in dye uptake and in maintaining release during prolonged stimulations as the eps15 and dap160 single mutants, suggesting that both Eps15 and Dap160 act at the same step in endocytosis. Furthermore, the notion that Eps15 is localized at the site of dynamin action is consistent with the mobilization of Eps15 to the plasma membrane in the vicinity of endocytic intermediates in stimulated nerve terminals (Figs. 2 Although we observed severe reduction of dynamin levels in both eps15 and dap160 mutants, there are subtle differences in synaptic protein levels between eps15 and dap160 mutants. For example, there is a reduction of synaptotagmin I in eps15 mutants, which was not observed in dap160 mutants. This may have resulted in minor differences in phenotypes, such as an increase in mEJP amplitudes in dap160 mutants but not in eps15 mutants. Eps15 has been implicated in clathrin-coated pit assembly in nonneuronal cells, based on its interaction with α-adaptin (Tebar et al., 1996; Carbone et al., 1997; Benmerah et al., 1999; Torrisi et al., 1999). However, our data indicate that a truncated Eps15 protein lacking the α-adaptin–interacting DPF motifs (ΔDPF) partially rescues the FM1-43FX uptake defect of the eps15-null mutant. This suggests that a direct interaction between Eps15 and α-adaptin is not essential for SV endocytosis. Consistent with the nonessential role of the DPF domain of Eps15, the Eps15 binding region of α-adaptin is not essential for the rescue of transferrin endocytosis after α-adaptin siRNA knockdown (Motley et al., 2006). Hence, we propose that the dynamin–Dap160–Eps15 interaction is important for SV endocytosis. A model of Eps15 function during SV endocytosis and synapse development Based on our data and previous work, we propose a two-tier model for Eps15 function during SV endocytosis and synapse development. During SV endocytosis, Eps15 and Dap160 act together to stabilize several proteins at the synapse. In particular, the Eps15–Dap160 complex maintains high concentrations of dynamin, allowing allosteric activation of its GTPase activity, which is crucial for the resolution of newly internalized membranes into SVs (Stowell et al., 1999). It has been proposed that actin polymerization propels endocytosed vesicles toward the interior of the cell during dynamin-mediated endocytosis (Merrifield et al., 2002; Shupliakov et al., 2002; Itoh et al., 2005; Tsujita et al., 2006). Given that Eps15, Dap160, and related EH domain proteins in yeast have been implicated in regulating the actin cytoskeleton (Tang and Cai, 1996; Duncan et al., 2001; Zamanian and Kelly, 2003; Koh et al., 2004; Marie et al., 2004), it is tempting to speculate that the Eps15–Dap160 complex functions as a molecular scaffold to coordinate dynamin function in SV endocytosis with actin polymerization, a role that has been previously proposed for Dap160 (McPherson, 2002). It is thus interesting that the redistribution of Eps15 and Dap160 within NMJ boutons during stimulation suggests a dynamic role of Eps15 and Dap160 during endocytosis (Fig. 2, F–I In addition to its role in SV endocytosis, Eps15 may function in concert with Dap160 during synapse development through regulation of signal transduction pathways and/or cytoskeletal organization. Both Eps15 and Dap160 have been implicated in signal transduction pathways (Irie and Yamaguchi, 2002; Polo et al., 2003). In addition, Dap160/intersectin has been proposed to regulate cytoskeletal organization at the Drosophila NMJ and in mammalian cells through interaction with actin-associated molecules like WASp (Zamanian and Kelly, 2003; Koh et al., 2004; Marie et al., 2004). This is consistent with our recent data on lamprey reticulospinal synapses, which show that actin at synaptic endocytic sties is reorganized when intersectin interactions are perturbed (Evergren et al., 2007). Interestingly, an EH domain protein is involved in cytoskeletal reorganization during budding of yeast cells (Tang and Cai, 1996; Duncan et al., 2001), which is thought to be analogous to Drosophila NMJ bouton formation (Pennetta et al., 2002). We speculate that Eps15 and Dap160 may function as a protein complex—with Nervous wreck and WASp—that regulates cytoskeletal organization during synapse development (Coyle et al., 2004; Koh et al., 2004; Marie et al., 2004). In this respect, Eps15 and Dap160 may serve to bridge upstream signal transduction pathways and cytoskeletal organization during synapse development. Materials and methods Antibody generation Two fragments encoding amino acid residues 586–816 and 915–1093 from Eps15 cDNA (SD09478 from Research Genetics) were cloned into the pGEX4T1 expression vector in frame with the GST coding region. GST-Eps15 (586–816) was used to generate the rabbit polyclonal antiserum, Rb Ab, and GST-Eps15 (915–1093) was used to generate guinea pig polyclonal antiserum, Gp Ab. Fly genetics P element excisions. w; EP(2)2513 (Rørth, 1996) was crossed to y1 w*; CyO, H{w+mC=PΔ2-3}HoP2.1/Bc1 EgfrE1 (Gerlitz et al., 2002) to generate 810 independent excision lines. Lines that failed to complement Df(2R)Dll-MP (Cohen et al., 1989) were characterized. Excisions were balanced over CyO, P{w+mC=Gal4-twi.G} P{w+mC=UAS-2xEGFP} (Halfon et al., 2002), and immunohistochemistry and Western blot were performed to identify allele eps15e75. Remnants of the P element are still inserted in its original genomic location, but the exact lesion is not known. FRT-mediated deletion. Two transposons carrying FRT elements, P{XP=FRT}d00445 and PBac{WH=FRT}f02085, were used for site-specific deletion of the eps15 locus as described previously (Parks et al., 2004). In brief, second chromosomes containing both transposons were placed in trans with each other in a genetic background containing P{ry+t7.2=hsFLP}12 (Bloomington Stock Center). 1-h 37°C heat-shock treatments were given to the larvae on three consecutive days to induce expression of the FLP recombinase. P{ry+t7.2=hsFLP}12, y1w*; P{XP=FRT}d00445/PBac{WH=FRT}f02085 females were then crossed to y1w*; L/CyO. In the next generation, dark-eyed males were isolated as putative recombinants and were crossed to eps15e75 to test for noncomplementation of lethality, leading to the isolation of the eps15Δ29 allele. About 80% of the dark-eyed males failed to complement eps15e75. PCR and sequencing showed that the junctions of P{XP=FRT}d00445 and PBac{WH=FRT}f0208 with their respective flanking DNA in the eps15 locus were retained in homozygous eps15Δ29 larvae, confirming recombination. Genomic rescue construct. 10.8 kb of genomic DNA containing the wild-type eps15 (2R region bp: 19811150–19821904; Berkeley Drosophila Genome Project release 3 [http://www.fruitfly.org/cgi-bin/annot/gbrowse]) was recovered from BAC RP98-3B7 (BACPAC Resources) by gap repair in the vector, 2.2B-1 P{acman} (Venken et al., 2006). In brief, we cloned 500-bp left and right homology arms separated by a BamHI site in P{acman}. The vector was linearized using BamHI and transformed into recombination-competent DH10B bacteria containing both BACRP98-3B7 and mini-λ-Tet (Court et al., 2003; Liu et al., 2003). Gap-repaired vectors were selected with Amp, screened by PCR, and verified by restriction enzyme digestion and sequencing. As a third chromosome insertion of this genomic construct, P{Eps15-S}3-2-2-5b, does not rescue homozygous eps15e75 mutants, we maintain eps15e75; P{Eps15-S}3-2-2-5b as a balanced line over a compound chromosome consisting of chromosomes 2 and 3. We then cross this line to eps15Δ29 and Df(2R)Dll-MP to test for rescue of lethality. The presence of the eps15 lesions was verified by homozygous lethality of the parental eps15Δ29 and Df(2R)Dll-MP stocks used for the final rescue cross. cDNA rescue constructs. Full-length Eps15 (Eps15wt), EHmut (full length with W54A, W174A, and W356A substitutions in the EH domains), and ΔDPF (residues 1–639) were subcloned from SD09478 cDNA into pUAST (Brand and Perrimon, 1993). eps15 cDNAs were driven by one of the elav-based neuronal drivers, the elavC155-Gal4 enhancer trap in the elav locus (Lin and Goodman, 1994), or an elav promoter Gal4 fusion transgene (elav-Gal43A4) inserted in the third chromosome (Luo et al., 1994). The elavC155-Gal4 driver drove higher transgene expression levels and rescued the lethality of eps15e75/eps15Δ29 more effectively than the third chromosome elav-Gal4 driver. Rescue of eps15 mutants was only observed when elavC155-Gal4 or elav-Gal43A4 was introduced in the same fly as the UAS-cDNA constructs. Presence of eps15 lesions in rescue individuals was verified by lethality associated with homozygosity on the second chromosome in the parental lines, eps15e75; UAS-cDNA, eps15Δ29; elav-Gal43A4, and C155; eps15Δ29.Larval culture Mutant larvae were separated from larvae bearing balancer chromosomes and cultured on grape juice agar with yeast paste (Loewen et al., 2001). This allows lethal phase of mutants to be determined without complications from overcrowding and competition from larvae bearing balancer chromosomes. Immunohistochemistry and quantification of fluorescent images Labeling of third instar NMJs, third instar brains, and adult brains was performed as described by Verstreken et al. (2003). Animals were dissected in PBS and fixed in 4% formaldehyde in PBS for 20 min. Tissue was extensively washed in PBS and permeabilized with 0.4% Triton X-100; for anti-endophilin labeling, permeabilization was performed using 0.1% Tween 20. Antibodies were used in the following dilutions: affinity-purified anti-Dap160, 1:500 (Roos and Kelly, 1998); mouse anti-Dlg, 1:150 (4F3; Parnas et al., 2001); rabbit anti-Dlg, 1:2,000 (Cho et al., 2000); guinea pig anti-Dlg, 1:500 (Parmentier et al., 2000); rabbit anti-HRP, 1:1,500 (Jackson ImmunoResearch Laboratories); rabbit anti–Stoned B, 1:200 (Andrews et al., 1996); mouse anti-Csp mAb 49, 1:20 (Zinsmaier et al., 1994); rat anti-Nwk, 1:500 (Coyle et al., 2004); rabbit anti-dynamin, 1:500 (Roos and Kelly, 1998); mouse anti-dynamin, 1:50 (clone 41; BD Biosciences); rabbit anti–α-adaptin, 1:50 (González-Gaitán and Jäckle, 1997); mouse anti–Fas II 1D4 guinea pig anti-endophilin, 1:200 (Verstreken et al., 2002); mouse anti-Bruchpilot nc82, 1:100 (Wagh et al., 2006); and anti–synaptotagmin I, 1:500 (Littleton et al., 1993, 1994). Secondary antibodies conjugated to Cy3 or Cy5 (Jackson ImmunoResearch Laboratories) or Alexa 488 or 594 (Invitrogen) were used at 1:250. Samples were mounted in Vectashield mounting medium (Vector Laboratories). For Fig. 2 (A, B, and E) For quantification of synaptic proteins, anti-Dlg labeling was used to outline type I boutons for quantification of synaptic protein levels (Lahey et al., 1994). Boutons on muscle 12 were scanned with z steps of 0.7 μm. Using Amira software, the Dlg-stained type I boutons in each confocal slice were highlighted, and the mean pixel intensity of all slices of the highlighted boutons of each muscle 12 NMJ were computed. Background fluorescence in muscle areas adjacent to the boutons was quantified similarly, and the background was subtracted from the bouton values to yield the mean intensity of labeling in the boutons. The mean value from at least three mutant NMJs was then expressed as a percentage of the corresponding control value. The primary antibodies against presynaptic proteins were used at concentrations that produced strong specific labeling in the NMJ boutons without giving excessive background labeling in other tissues. Biochemistry Immunoprecipitation experiments were performed essentially as described previously (Bean et al., 2000; Verstreken et al., 2003). The Dap160 band was detected by in-gel trypsin digest followed by peptide determination using a Q-STAR hybrid tandem mass spectrometer (MDS Sciex). Spectra were searched against a NCBI nonredundant database with MASCOT MS/MS Ions search (Matrix Science). The only other two Coomassie blue–stained bands that were successfully identified were keratin (likely a contaminant from the experimenter) and CG5214, a mitochondrial enzyme in the tricarboxylic acid cycle. For Western blots, rabbit anti-Eps15 was used at 1:2,500, rabbit anti–α-adaptin (Dornan et al., 1997) at 1:200, rabbit anti-dynamin (Roos and Kelly, 1998) at 1:300, and rabbit anti-Dap160 (Roos and Kelly, 1998) at 1:500. For pull-down assays, Histidine (His)-tagged and GST fusion proteins were expressed in BL21(DE3)pLysS (Novagen) cells and purified from soluble fraction using Ni-NTA (QIAGEN) and glutathione (GE Healthcare) beads, respectively, before being used for binding assays. Ni-NTA agarose-coupled His-tagged UIM region of Eps15 (amino acids 1177–1253) was incubated with GST or GST-Ubiquitin (G76A; Lloyd et al., 2002) for 2 h at 4°C, washed extensively in PBS (0.01 M phosphate buffer, 0.0027 M KCl, and 0.137 M NaCl, pH 7.4) supplemented with 0.1% Triton X-100 and Complete protein inhibitor cocktail (Roche) and prepared for electrophoresis. For pull downs from fly head extracts, glutathione Sepharose–coupled GST, GST-3xEH (amino acides 1–403), and the GST-DPF region of Eps15 (amino acids 551–1001) were incubated with extracts (frozen heads homogenized in PBS supplemented with 2 mM CaCl2, 1.5 mM MgCl2, 1% Triton X-100, and Complete protein inhibitor cocktail; cleared soluble fraction adjusted to 0.1% Triton X-100 concentration) for 2 h at 4°C, washed extensively in the same buffer, and prepared for electrophoresis. Electrophysiology and FM1-43FX uptake assay Third instar electrophysiology was also performed essentially as described previously (Verstreken et al., 2002, 2003). Larvae were dissected, and recordings were performed in modified HL3: 110 mM NaCl; 5 mM KCl; 10 mM NaHCO3; 5 mM Hepes; 30 mM sucrose; 5 mM trehalose; 10 mM MgCl2; and 0, 0.5, or 5 mM CaCl2 (as indicated in the text and figure legends). For 10-Hz stimulations, the above medium was modified to contain 4 mM MgCl2 and 5 mM CaCl2. Recordings of low-frequency stimulations and 10-Hz stimulations were made from muscles with resting potential lower than −60 and −65 mV, respectively. For the FM1-43FX (Invitrogen) styryl dye uptake experiments, larvae were dissected on Sylgard plates and incubated in modified HL3 with 4 μM FM1-43FX, 5 mM CaCl2, 90 mM KCl, and 25 mM NaCl for 10 min. Excess dye was then washed away with zero Ca2+ solution for 10–15 min, and labeling was imaged using a 40×/0.75w Acroplan water-immersion lens on the LSM 510 confocal microscope. Data acquisition as well as data processing and quantification were performed as described previously (Verstreken et al., 2003). The FM1-43FX dye uptake assay in Fig. 8 TEM Larval fillets were prepared in HL3 without Ca2+ and fixed in 4% paraformaldehyde/1% glutaraldehyde/0.1 M cacodylic acid, pH 7.2, or 3% paraformaldehyde/0.5% glutaraldehyde/0.1 M cacodylic acid, pH 7.2. Samples were postfixed in 2% OsO4 and stained in 2% uranyl acetate, dehydrated in alcohol, and embedded in Spurr's resin (Electron Microscopy Sciences) or Durcupan (Fluka). Ultrathin sections were cut with a diamond knife (Diatome) and stained with 2% uranyl acetate and lead citrate on grids. The grids were then visualized with an electron microscope (JEM-1010; JEOL) fitted with a charge-coupled device digital camera (Gatan). To study the morphology of stimulated boutons, larval fillets were incubated in HL3 with 5 mM Ca2+ and 60 or 90 mM K+ for 10 min and fixed immediately. In stimulation-recovery experiments, stimulated NMJs were allowed to recover for 1 min in normal HL3 without Ca2+ before fixation. Images were quantified by NIH ImageJ. Preembedding immunocytochemistry Muscles 6 and 7 were dissected from third instar Drosophila larvae were fixed in 4% paraformaldehyde and embedded in agarose (Sigma-Aldrich). Vibratome slices of the agarose blocks were incubated with guinea pig anti-Eps15 antiserum followed by secondary antibodies conjugated to 1.4-nm gold particles (Nanoprobes, Inc.). The immunogold labeling was silver enhanced using IntenSE Silver Enhancement kit (GE Healthcare), and samples were embedded in Durcupan ACM (Fluka) for ultrathin sectioning. Serial ultrathin sections were counterstained with uranyl acetate and lead citrate and examined in a microscope (Tecnai 12; FEI Company). Images were quantified using NIH ImageJ, and statistical evaluation was performed using Excel (Microsoft). Note that the silver enhancement technique works by the precipitation of silver particles around the gold particles, resulting in the formation of irregularly shaped black precipitates. Online supplemental material Fig. S1 illustrates the domain structure of Drosophila Eps15 and shows that the eps15-null alleles do not express detectable amounts of Eps15. Fig. S2 shows that mBSA endocytosis and dynamin levels are both normal in eps15-null hemocytes. Fig. S3 shows that dynamin and Dap160 levels are not substantially altered in the larval brains of eps15 mutants. Fig. S4 shows that the EH, DPF, and UIM domains of Eps15 bind to Dap160, α-adaptin, and ubiquitin, respectively. Table S1 shows mass spectroscopy data of peptide sequences corresponding to Dap160, which coimmunoprecipitated with Eps15 (Fig. 1 A). Online supplemental material is available at http://www.jcb.org/cgi/content/full/jcb.200701030/DC1. [Supplemental Material Index]
Acknowledgments We are grateful to C.-K. Yao for critical assessment of data on bouton morphology, and we thank H. McMahon for mass spectroscopy, Y.-T. Lei for quantification of morphological data, N. Tomilin for expert advice in EM, and K.S. Krishnan and A. Majumdar for sharing results and reagents before publication. In addition, we are grateful to K.W. Cho, R. Kelly, L. Kelly, B. Ganetzky, M. González-Gaitán, E. Buchner, and A. Jackson for antibodies; D. Court for mini-λ-Tet; and P. Verstreken, A. Fayyazudin, and C. Ly for critical comments on this manuscript. We acknowledge stocks and antibodies from the Bloomington and Szeged Drosophila stock centers and the Developmental Biology Hybridoma Center, Iowa. Confocal microscopy was supported by the Mental Retardation and Developmental Disabilities Research Center. T.-W. Koh acknowledges support from the Baylor College of Medicine–Karolinska Institutet Exchange Program. Y.P. Wairkar was supported by a Nehru scholarship from the Cambridge Commonwealth Trust. This work was supported by a grant (8/C19002) and a Research Development Fellowship from the Biotechnology and Biological Sciences Research Council to C.J. O'Kane, a Career Development Award (G120/414) from the Medical Research Council to I.M. Robinson, fellowship from Hjärnfonden to E. Evergren, The Swedish Research Council (13473) and Fernströms Stiftelse to O. Shupliakov, and a Howard Hughes Institutional Grant (76200-549202) to I.M. Robinson. H.J. Bellen is supported by the Howard Hughes Medical Institute. Notes T.-W. Koh and V.I. Korolchuk contributed equally to this paper. T.-W. Koh's present address is Department of Molecular, Cellular, and Developmental Biology, Yale University, New Haven, CT 06511. V.I. Koroluchuk's present address is School of Clinical Medicine, Cambridge Institute for Medical Research, Cambridge CB2 0XY, UK. Y.P. Wairkar's present address is Department of Molecular Biology and Pharmacology, School of Medicine, Washington University in St. Louis, St. Louis, MO 63110. Abbreviations used in this paper: Dap160, dynamin-associated protein 160 kD; EH, Eps15 homology; EJP, excitatory junctional potential; Eps15, EGF receptor pathway substrate clone 15; FRT, FLP recognition target; mEJP, miniature EJP; NMJ, neuromuscular junction; SV, synaptic vesicle; TEM, transmission EM; UIM, ubiquitin-interacting motif. References
|
PubMed related articles
Your browsing activity is empty. Activity recording is turned off. |
|||||||||||||||||||||||
Neuron. 2000 Aug; 27(2):301-12.
[Neuron. 2000]J Neurosci. 2000 Nov 1; 20(21):7986-93.
[J Neurosci. 2000]Nature. 2002 May 30; 417(6888):555-9.
[Nature. 2002]Neuron. 2006 Sep 21; 51(6):773-86.
[Neuron. 2006]Nature. 2006 Nov 2; 444(7115):102-5.
[Nature. 2006]Curr Biol. 2004 Oct 5; 14(19):R853-5.
[Curr Biol. 2004]Neuron. 2004 Jul 22; 43(2):193-205.
[Neuron. 2004]Neuron. 2004 Jul 22; 43(2):207-19.
[Neuron. 2004]J Neurosci. 2007 Jan 10; 27(2):379-90.
[J Neurosci. 2007]Exp Cell Res. 1999 Nov 25; 253(1):186-209.
[Exp Cell Res. 1999]EMBO J. 1999 Mar 1; 18(5):1159-71.
[EMBO J. 1999]Nat Cell Biol. 2001 Aug; 3(8):755-60.
[Nat Cell Biol. 2001]Mol Cell Biol. 1993 Sep; 13(9):5814-28.
[Mol Cell Biol. 1993]Mol Cell Biol. 1996 Sep; 16(9):4897-914.
[Mol Cell Biol. 1996]Neuron. 2000 Apr; 26(1):45-50.
[Neuron. 2000]Nature. 2002 Mar 28; 416(6879):451-5.
[Nature. 2002]EMBO J. 1999 Mar 1; 18(5):1159-71.
[EMBO J. 1999]J Cell Sci. 1999 May; 112 ( Pt 9)():1303-11.
[J Cell Sci. 1999]Nat Cell Biol. 2001 Aug; 3(8):755-60.
[Nat Cell Biol. 2001]Neuron. 2000 Apr; 26(1):45-50.
[Neuron. 2000]Genetics. 1994 Jun; 137(2):551-63.
[Genetics. 1994]Nat Genet. 2004 Mar; 36(3):283-7.
[Nat Genet. 2004]Nat Cell Biol. 2001 Aug; 3(8):755-60.
[Nat Cell Biol. 2001]Neuron. 1994 Oct; 13(4):823-35.
[Neuron. 1994]J Cell Biol. 2003 May 12; 161(3):609-24.
[J Cell Biol. 2003]Neuron. 2006 Mar 16; 49(6):833-44.
[Neuron. 2006]Curr Biol. 1999 Dec 2; 9(23):1411-4.
[Curr Biol. 1999]J Neurosci. 1996 Sep 1; 16(17):5443-56.
[J Neurosci. 1996]Neuron. 2002 May 30; 34(5):729-41.
[Neuron. 2002]Neuron. 2004 Jul 22; 43(2):193-205.
[Neuron. 2004]Neuron. 2004 Jul 22; 43(2):207-19.
[Neuron. 2004]J Biol Chem. 1996 Nov 15; 271(46):28727-30.
[J Biol Chem. 1996]J Cell Sci. 1999 May; 112 ( Pt 9)():1303-11.
[J Cell Sci. 1999]Mol Biol Cell. 1999 Feb; 10(2):417-34.
[Mol Biol Cell. 1999]J Biol Chem. 2003 Apr 4; 278(14):12513-21.
[J Biol Chem. 2003]Nat Cell Biol. 2001 Aug; 3(8):755-60.
[Nat Cell Biol. 2001]Neuron. 2004 Jul 22; 43(2):193-205.
[Neuron. 2004]Neuron. 2004 Jul 22; 43(2):193-205.
[Neuron. 2004]Cell. 2002 Apr 5; 109(1):101-12.
[Cell. 2002]Exp Cell Res. 2006 Jul 15; 312(12):2288-98.
[Exp Cell Res. 2006]Neuron. 2004 Jul 22; 43(2):193-205.
[Neuron. 2004]Neuron. 2004 Jul 22; 43(2):193-205.
[Neuron. 2004]Neuron. 2004 Jul 22; 43(2):207-19.
[Neuron. 2004]Cell. 2002 Apr 5; 109(1):101-12.
[Cell. 2002]Neuron. 2003 Nov 13; 40(4):733-48.
[Neuron. 2003]J Biol Chem. 1998 Jul 24; 273(30):19108-19.
[J Biol Chem. 1998]J Cell Biol. 1998 Mar 9; 140(5):1055-62.
[J Cell Biol. 1998]EMBO J. 1999 Mar 1; 18(5):1159-71.
[EMBO J. 1999]Nature. 2002 Mar 28; 416(6879):451-5.
[Nature. 2002]J Cell Sci. 1999 May; 112 ( Pt 9)():1303-11.
[J Cell Sci. 1999]Exp Cell Res. 1999 Nov 25; 253(1):186-209.
[Exp Cell Res. 1999]EMBO J. 1999 Mar 1; 18(5):1159-71.
[EMBO J. 1999]Neuron. 2004 Jul 22; 43(2):193-205.
[Neuron. 2004]Neuron. 2004 Jul 22; 43(2):207-19.
[Neuron. 2004]Neuron. 2004 Jul 22; 43(2):193-205.
[Neuron. 2004]J Cell Sci. 1999 May; 112 ( Pt 9)():1303-11.
[J Cell Sci. 1999]EMBO J. 1999 Mar 1; 18(5):1159-71.
[EMBO J. 1999]J Cell Biol. 2001 May 28; 153(5):1111-20.
[J Cell Biol. 2001]Nat Cell Biol. 2001 Aug; 3(8):755-60.
[Nat Cell Biol. 2001]J Biol Chem. 2000 Apr 28; 275(17):12752-6.
[J Biol Chem. 2000]J Neurosci. 2000 Nov 1; 20(21):7986-93.
[J Neurosci. 2000]J Physiol. 2003 Dec 1; 553(Pt 2):345-55.
[J Physiol. 2003]J Neurobiol. 1983 May; 14(3):207-25.
[J Neurobiol. 1983]J Neurosci. 1989 Nov; 9(11):3844-60.
[J Neurosci. 1989]J Cell Biol. 1996 Nov; 135(3):797-808.
[J Cell Biol. 1996]J Neurophysiol. 1999 Apr; 81(4):1495-505.
[J Neurophysiol. 1999]J Neurosci. 1993 Jun; 13(6):2313-22.
[J Neurosci. 1993]J Biol Chem. 1996 Nov 15; 271(46):28727-30.
[J Biol Chem. 1996]Cancer Res. 1997 Dec 15; 57(24):5498-504.
[Cancer Res. 1997]J Cell Sci. 1999 May; 112 ( Pt 9)():1303-11.
[J Cell Sci. 1999]Mol Biol Cell. 1999 Feb; 10(2):417-34.
[Mol Biol Cell. 1999]Mol Biol Cell. 2006 Dec; 17(12):5298-308.
[Mol Biol Cell. 2006]Nat Cell Biol. 1999 May; 1(1):27-32.
[Nat Cell Biol. 1999]Nat Cell Biol. 2002 Sep; 4(9):691-8.
[Nat Cell Biol. 2002]Proc Natl Acad Sci U S A. 2002 Oct 29; 99(22):14476-81.
[Proc Natl Acad Sci U S A. 2002]Dev Cell. 2005 Dec; 9(6):791-804.
[Dev Cell. 2005]J Cell Biol. 2006 Jan 16; 172(2):269-79.
[J Cell Biol. 2006]Nat Neurosci. 2002 Nov; 5(11):1117-8.
[Nat Neurosci. 2002]Mol Biol Cell. 2003 Apr; 14(4):1624-37.
[Mol Biol Cell. 2003]Neuron. 2004 Jul 22; 43(2):193-205.
[Neuron. 2004]Neuron. 2004 Jul 22; 43(2):207-19.
[Neuron. 2004]J Neurosci. 2007 Jan 10; 27(2):379-90.
[J Neurosci. 2007]Proc Natl Acad Sci U S A. 1996 Oct 29; 93(22):12418-22.
[Proc Natl Acad Sci U S A. 1996]Int J Dev Biol. 2002 Jan; 46(1):173-6.
[Int J Dev Biol. 2002]Nature. 1989 Mar 30; 338(6214):432-4.
[Nature. 1989]Genesis. 2002 Sep-Oct; 34(1-2):135-8.
[Genesis. 2002]Nat Genet. 2004 Mar; 36(3):288-92.
[Nat Genet. 2004]Science. 2006 Dec 15; 314(5806):1747-51.
[Science. 2006]Gene. 2003 Oct 2; 315():63-9.
[Gene. 2003]Genome Res. 2003 Mar; 13(3):476-84.
[Genome Res. 2003]Development. 1993 Jun; 118(2):401-15.
[Development. 1993]Neuron. 1994 Sep; 13(3):507-23.
[Neuron. 1994]Genes Dev. 1994 Aug 1; 8(15):1787-802.
[Genes Dev. 1994]Genesis. 2001 Sep; 31(1):30-6.
[Genesis. 2001]Neuron. 2003 Nov 13; 40(4):733-48.
[Neuron. 2003]J Biol Chem. 1998 Jul 24; 273(30):19108-19.
[J Biol Chem. 1998]Neuron. 2001 Nov 8; 32(3):415-24.
[Neuron. 2001]Cell. 2000 Oct 13; 103(2):331-42.
[Cell. 2000]Genetics. 1996 Aug; 143(4):1699-711.
[Genetics. 1996]Neuron. 1994 Oct; 13(4):823-35.
[Neuron. 1994]J Biol Chem. 2000 May 19; 275(20):15271-8.
[J Biol Chem. 2000]Neuron. 2003 Nov 13; 40(4):733-48.
[Neuron. 2003]Mol Biol Cell. 1997 Aug; 8(8):1391-403.
[Mol Biol Cell. 1997]J Biol Chem. 1998 Jul 24; 273(30):19108-19.
[J Biol Chem. 1998]Cell. 2002 Jan 25; 108(2):261-9.
[Cell. 2002]Cell. 2002 Apr 5; 109(1):101-12.
[Cell. 2002]Neuron. 2003 Nov 13; 40(4):733-48.
[Neuron. 2003]Neuron. 2003 Nov 13; 40(4):733-48.
[Neuron. 2003]